Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genetic Analysis ASXSAT:GEAN -2.94%34 Days Payable is 202.44 as of Mar. 2026, which is 52% below its 10-year median of 420.15. GuruFocus rates XSAT:GEAN with a GF Score™ of 34/100 and a GF Value™ of kr0.54 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 190 Medical Diagnostics & Research companies, Genetic Analysis AS ranks better than 83.68% on this metric.
The historical rank and industry rank for Genetic Analysis AS's Days Payable or its related term are showing as below:
XSAT:GEAN'
s Days Payable Range Over the Past 10 Years
Min: 188.62 Med: 420.15 Max: 601.55
Current: 252.44
During the past 7 years, Genetic Analysis AS's highest Days Payable was 601.55. The lowest was 188.62. And the median was 420.15.
XSAT:GEAN's Days Payable is ranked better than 83.68% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 64.64
vs XSAT:GEAN: 252.44
Genetic Analysis AS's Days Payable
declined
from Mar. 2025 (1,062.43) to Mar. 2026 (202.44).
It may suggest that Genetic Analysis ASaccelerated paying its suppliers.
Genetic Analysis AS Days Payable Related Terms
Genetic Analysis AS Days Payable Historical Data
* Premium members only.
The historical data trend for Genetic Analysis AS's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSAT:GEAN vs TMO, DHR, IDXX: Days Payable Comparison
For the Diagnostics & Research subindustry, Genetic Analysis AS's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genetic Analysis AS Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Analysis AS's Days Payable distribution charts can be found below:
* The bar in red indicates where Genetic Analysis AS's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Genetic Analysis AS's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genetic Analysis AS (XSAT:GEAN) has a Days Payable of 202.44 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Genetic Analysis AS and its competitors. This is 52% below median its historical median of 420.15. Over the past decade, Genetic Analysis AS's Days Payable has ranged from 188.62 to 601.55. According to the industry distribution chart, Genetic Analysis AS ranks #31 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 16.3%.
Is Genetic Analysis AS's Days Payable too high?
Genetic Analysis AS's current Days Payable of 202.44 is 52% below median its 10-year median of 420.15. Over the past 10 years, this metric has ranged from a low of 188.62 to a high of 601.55. The Medical Diagnostics & Research industry median Days Payable is 64.64. Genetic Analysis AS's value of 202.44 is 213.2% above this industry median. Based on the distribution chart, Genetic Analysis AS ranks #31 out of 190 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Genetic Analysis AS has a GF Score™ of 34/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Genetic Analysis AS's Days Payable compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Genetic Analysis AS ranks #31 out of 190 companies for Days Payable. This places Genetic Analysis AS in the top 16% of its industry — outperforming the majority of peers. The industry median Days Payable is 64.64. Genetic Analysis AS's value of 202.44 is 213.2% above this benchmark. Historically, Genetic Analysis AS's own Days Payable has ranged from 188.62 to 601.55 over the past decade. While the company's 10-year median is 420.15 vs. the industry median of 64.64, Genetic Analysis AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 64.64, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genetic Analysis AS's current Days Payable of 202.44 is 213.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Genetic Analysis AS and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 64.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genetic Analysis AS's current Days Payable is 202.44, which is 52% below median its own 10-year median of 420.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Analysis AS stock overvalued right now?
Based on GuruFocus' analysis, Genetic Analysis AS (XSAT:GEAN) is currently considered Modestly Overvalued. The stock's GF Value™ is kr0.54, compared to a current price of kr0.66 — trading 22.2% above its estimated fair value. The current Days Payable is 202.44, which is 52% below median its 10-year median of 420.15 and 213.2% above the Medical Diagnostics & Research industry median of 64.64. Genetic Analysis AS's overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Genetic Analysis AS (XSAT:GEAN), the current Days Payable is 202.44 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genetic Analysis AS (XSAT:GEAN) Overvalued in 2026?
Based on GuruFocus' analysis, Genetic Analysis AS stock appears to be overvalued.
The current stock price of kr0.66 is trading 22.2% above its estimated GF Value™ of kr0.54.
GuruFocus considers Genetic Analysis AS to be Modestly Overvalued.
Key valuation signals for XSAT:GEAN:
Days Payable: 202.44 (52% below median its 10-year median of 420.15)
GF Value™: kr0.54 vs. price of kr0.66 (22.2% above fair value)
Industry Position: 213.2% above the Medical Diagnostics & Research median (#31 of 190)
No single metric tells the full story. See the XSAT:GEAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genetic Analysis AS is a research-driven diagnostic company dedicated to delivering diagnostic solutions to the growing human microbiota market. It is providing a CE-marked gut microbiota analysis for testing bacterial imbalance in IBS and IBD patients. Geographically, it operates in the USA, Europe, and the Rest of the world. Geographically, the company sells products in the USA, Europe, and the rest of the world. The majority of its revenue is generated from the USA. The GA-map technology platform and product portfolio are currently used across three main market segments: Clinical diagnostics, research (academic and industry), and Consumer Health.
34GF Score
Get the complete analysis for XSAT:GEAN
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:GEAN has been successfully added to your 
